

Jennifa Gosling, et al.
Application No.: 09/686,019
Page 3

PATENT

40. (New) The method of claim 37, wherein the cell expresses a recombinant CCX CKR polypeptide, fragment or variant.

41. (New) The method of claim 37, wherein the chemokine is ELC.

42. (New) The method of claim 37, wherein the chemokine is SLC.

43. (New) The method of claim 37, wherein the chemokine is TECK.

44. (New) The method of claim 37, wherein the chemokine is BLC.

45. (New) The method of claim 37, wherein the chemokine is CTACK.

46. (New) The method of claim 37, wherein the chemokine is mMIP-1 γ .

47. (New) The method of claim 37, wherein the chemokine is vMIPII.

48. (New) A process for providing a pharmaceutical composition, comprising conducting the steps of a method of claim 37 and thereafter formulating a modulator of CCX CKR activity for pharmaceutical use.--

REMARKS

I. Status of Claims

Claims 1-36 are currently pending, with claims 1-36 canceled without prejudice or disclaimer and new claims 37-48 introduced upon entry of this amendment. These new claims are directed to the subject matter of one group of claims as restricted in related application 09/686,020. The claims are also intended to focus on subject matter of particular commercial value. Thus, this amendment is not made for reasons of patentability.

The new claims find support throughout the specification including, for example, the following sections;

Claim 37: Original claims 29-31; page 33-38; example 7 on